I

n a highly anticipated decision, the U.S. Supreme Court reduced the time that companies will have to wait before selling lower-cost versions of expensive biologic medicines, a move that is expected to save the health care system piles of money.

The 9-to-0 ruling came in response to sharply contrasting views of the complex procedures found in the Biologics Price Competition and Innovation Act, which is supposed to determine when biosimilar drugs can be launched. In this instance, Sandoz and Amgen are squabbling over competing interpretations.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.